Have $2,000? 2 Unbelievable Growth Stocks You Can Buy on Sale

In the words of Warren Buffett, “Whether we’re talking about socks or stocks, I like buying quality merchandise when it is marked down.” While price alone should never determine whether you buy a stock, Buffett’s sentiment is worth remembering for long-term investors.

When you buy and hold stocks for years, you’re likely to see shares fluctuate over time along with the broader market. In today’s rather turbulent market, while many stocks are overpriced, a number of top growth stocks with great underlying businesses have fallen from pandemic highs. This creates an opportunity for shrewd long-term investors to snag great buys on the cheap.

If you’re going bargain hunting this week, here are two stellar stocks for your consideration.

Teladoc

The world’s largest telehealth provider became a household name in the early days of the pandemic as lockdowns and overwhelmed healthcare systems compelled patients to look for alternative ways to get the care they needed when they needed it.

Although shares of Teladoc (NYSE:TDOC) have dropped about 30% over the past year as the hype surrounding stay-at-home stocks has died down, its growth has remained steadily on course. It’s also worth noting that shares of the healthcare stock have appreciated by about 676% over the trailing-five-year period, considerably above the 107% return delivered by the S&P 500 in the same window of time.

Teladoc’s penchant for rapid revenue growth didn’t start with the pandemic. For instance, in 2019, the company reported that its top line jumped by a whopping 32% from the prior year. And that same year, total visits conducted on Teladoc’s platform surged 57% higher than in 2018.

In the most recent quarterly report, for the period ending June 30, the healthcare stock reported that its revenue was up 109% year over year. In addition, total visits on its platform jumped nearly 30% from the year-ago quarter. During the three-month period, Teladoc expanded its already considerable stable of healthcare services with the launch of myStrength Complete, which it describes as “an integrated mental health service that combines app-based tools and coaching expertise with Teladoc’s therapists and psychiatrists.” 

The company finished the second quarter with about $784 million in cash and cash equivalents and just about $276 million of debt due within the next year. In fact, it was such an illustrious quarter of growth for Teladoc that management raised its full-year guidance again, after having done so in the previous quarterly report. It now projects upward of 80% revenue growth for full-year 2021.

Shares of Teladoc may not be flying as high as they were a year ago. But its prospects as the leader in its industry (which is expected to hit a global valuation of nearly $500 billion by 2026) remain unchanged. Teladoc continues to add quarter after quarter of strong growth to an already stellar track record. Long-term…